Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of inhaled CHF 6001 in COPD on background therapy
2015-005548-32Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tanimilast in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Predose FEV1 at 12 weeks. Started Jul 2016; status: completed.
02
Drugs
tanimilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2015-005548-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005548-32.